BioMarin Pharmaceuticals Inc (BMRN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

BioMarin Pharmaceuticals ( BMRN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.5%. By the end of trading, BioMarin Pharmaceuticals rose 63 cents (1.7%) to $37.41 on heavy volume. Throughout the day, 2.3 million shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in a price between $36.28-$37.60 after having opened the day at $36.81 as compared to the previous trading day's close of $36.78. Other companies within the Drugs industry that increased today were: Aoxing Pharmaceutical Company ( AXN), up 17%, Dendreon ( DNDN), up 16.1%, Anthera Pharmaceuticals ( ANTH), up 13.5%, and Threshold Pharmaceuticals ( THLD), up 9.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $4.58 billion and is part of the health care sector. The company has a P/E ratio of -48.7, below the S&P 500 P/E ratio of 17.7. Shares are up 7% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

On the negative front, Novogen ( NVGN), down 24.1%, Natures Sunshine Products ( NATR), down 15.5%, Endocyte ( ECYT), down 14.1%, and Corcept Therapeutics ( CORT), down 12.9%, were all laggards within the drugs industry with Eli Lilly and Company ( LLY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.